Applying for vaccine support?

Learn about the science and impact of these vaccines

COVID-19 vaccine support

Gavi is a co-convener of COVAX, the leading supplier of free COVID-19 vaccines to low-income countries.

See vaccine

Gavi is a co-convener of COVAX, the leading supplier of free COVID-19 vaccines to low-income countries.

See vaccine

Ebola vaccine support

Gavi led efforts to fund and deploy the world’s first Ebola vaccine, launching a global stockpile in 2021.

See vaccine

Gavi led efforts to fund and deploy the world’s first Ebola vaccine, launching a global stockpile in 2021.

See vaccine

HPV vaccine support

Safe and effective human papillomavirus (HPV) vaccine offers protection against at least 70% of all cervical cancer cases.

See vaccine

Safe and effective human papillomavirus (HPV) vaccine offers protection against at least 70% of all cervical cancer cases.

See vaccine

Inactivated polio vaccine support

Countries are now introducing a second dose of inactivated polio vaccine (IPV) with full Gavi support.

See vaccine

Countries are now introducing a second dose of inactivated polio vaccine (IPV) with full Gavi support.

See vaccine

Japanese encephalitis vaccine support

Gavi supports the introduction of the Japanese encephalitis (JE) vaccine into routine immunisation programmes, and funds catch-up campaigns.

See vaccine

Gavi supports the introduction of the Japanese encephalitis (JE) vaccine into routine immunisation programmes, and funds catch-up campaigns.

See vaccine

Malaria vaccine support

Gavi supports the roll-out of the world’s first malaria vaccine – nearly 35 years in development – in sub-Saharan Africa.

See vaccine

Gavi supports the roll-out of the world’s first malaria vaccine – nearly 35 years in development – in sub-Saharan Africa.

See vaccine

Measles and measles-rubella vaccine support

Gavi-supported measles and measles-rubella vaccines protect against two devastating diseases.

See vaccine

Gavi-supported measles and measles-rubella vaccines protect against two devastating diseases.

See vaccine

Meningococcal vaccine support

Gavi-supported introductions into routine immunisation programmes and campaigns with meningococcal A vaccine have reached more than 395 million people, in addition to those reached through the Gavi-funded multivalent meningococcal vaccine stockpile for outbreak response.

See vaccine

Gavi-supported introductions into routine immunisation programmes and campaigns with meningococcal A vaccine have reached more than 395 million people, in addition to those reached through the Gavi-funded multivalent meningococcal vaccine stockpile for outbreak response.

See vaccine

Oral cholera vaccine support

Gavi helps to prevent cholera outbreaks and control endemic cholera through its support to the Global Oral Cholera Vaccine (OCV) Stockpile and preventive OCV programme.

See vaccine

Gavi helps to prevent cholera outbreaks and control endemic cholera through its support to the Global Oral Cholera Vaccine (OCV) Stockpile and preventive OCV programme.

See vaccine

Pentavalent vaccine support

Find out more about Gavi’s support for the pentavalent vaccine, which protects against five deadly diseases.

See vaccine

Find out more about Gavi’s support for the pentavalent vaccine, which protects against five deadly diseases.

See vaccine

Pneumococcal conjugate vaccine support

Learn how Gavi helps countries fight pneumonia – which killed more than 740,000 children aged under 5 in 2019 alone.

See vaccine

Learn how Gavi helps countries fight pneumonia – which killed more than 740,000 children aged under 5 in 2019 alone.

See vaccine

Rotavirus vaccine support

Gavi supports countries to introduce and roll out the rotavirus vaccine, protecting against severe and deadly diarrhoea that killed ~370,000 children globally in 2019.

See vaccine

Gavi supports countries to introduce and roll out the rotavirus vaccine, protecting against severe and deadly diarrhoea that killed ~370,000 children globally in 2019.

See vaccine

Typhoid conjugate vaccine support

Gavi funding for the new typhoid conjugate vaccine (TCV), which protects against typhoid fever and can curb antimicrobial resistance, became available in 2018.

See vaccine

Gavi funding for the new typhoid conjugate vaccine (TCV), which protects against typhoid fever and can curb antimicrobial resistance, became available in 2018.

See vaccine

Yellow fever vaccine support

Gavi provides yellow fever vaccine support for its introduction into routine immunisation programmes, as well as funding for campaigns in high-risk countries and an emergency stockpile in case of outbreaks.

See vaccine

Gavi provides yellow fever vaccine support for its introduction into routine immunisation programmes, as well as funding for campaigns in high-risk countries and an emergency stockpile in case of outbreaks.

See vaccine
Last updated: 6 Nov 2023

Subscribe to our newsletter